Organon rises after update on independent review
Source: SeekingAlpha
2026-02-20 08:20:06 ET
More on Organon
- Organon & Co. 2025 Q4 - Results - Earnings Call Presentation
- Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
- Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
- Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage
- Organon falls as women’s health unit drives Q4 miss
Read the full article on Seeking Alpha
For further details see:
Organon rises after update on independent review
Organon & Co.
NASDAQ: OGN
OGN Trading
1.66% G/L:
$6.415 Last:
922,035 Volume:
$6.34 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
